All In Biotech

Free tool

FAERS Monitor: Cimerli

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761165 or its brand name (Cimerli, Ranibizumab-Eqrn). Reports on generic versions are filed under their own applications.

Reports

162

Serious

22

14% of reports

Hospitalization

0

Death reported

7

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective62
  • underdose54
  • product administration error13
  • product contamination9
  • product storage error8
  • visual impairment8
  • circumstance or information capable of leading to medication error7
  • death7
  • product use issue6
  • endophthalmitis5
  • product dose omission issue5
  • vision blurred5
  • off label use4
  • wrong technique in product usage process4
  • burning sensation3

Reports by year received

View as table
YearReports
202314
202468
202522
202658

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,997 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
product contaminationSignal9329.1174.32,619
endophthalmitisSignal5108.345.7429
underdoseSignal5496.177.35,002
product administration errorSignal1383.649.6980
circumstance or information capable of leading to medication errorSignal726.913.0150
product storage errorSignal811.96.069
visual impairmentSignal88.44.345
drug ineffectiveSignal626.15.0277
burning sensationSignal35.61.87
vision blurredSignal54.72.011
product use issueSignal64.11.911
wrong technique in product usage process42.61.02
product dose omission issue52.20.92
death71.10.50
off label use40.60.21

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.